Skip to main content
. 2019 Oct;7(20):572. doi: 10.21037/atm.2019.09.18

Figure 1.

Figure 1

OS (A) and PFS (B) stratified by Systemic Immune-Inflammation Index (SII) in patients treated with first-line therapy for locally advanced or metastatic NSCLC. NSCLC, non-small cell lung cancer; PFS, progression free survival; OS, overall survival.